Skip to main content
Ying Jin on Muck Rack

Ying Jin

As seen in: Color Research & Application, Nature, Wiley, Wiley Online Library, PLOS ONE, BMJ Open Respiratory Research, Elsevier, Frontiers, MDPI, SAGE Publishing and
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Ying

Contact Ying, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

ERK1/2 function as a central hub safeguarding primed human embryonic stem cell identity via multifaceted regulatory networks

|
By Yifan Zhou, Hanzhi T. Zhao, Min Shao, Huiyuan Jiao, Lingjie Li, Ying Jin, Weixuan Lu
| Cell Reports Verified
Results To systematically define the function of ERK1 and ERK2 in hESCs, we utilized stepwise CRISPR-Cas9n genetic editing methods to deplete ERK1 and ERK2 in hESCs (Figure 1A and S1A). Briefly, CRE hESCs constitutively expressing ERT2CREERT2 served as control cells. The inducible KO (iKO) of ERK1 or ERK2 was achieved by 4-hydroxytamoxifen (4OHT)-mediated recombination of LoxP sites. An ERK1/2 iKO line (ERK1Δ/Δ; ERK2fl/-) was generated from the ERK1 KO line.
Open in Who Shared Issue with article?

Computer Science > Machine Learning

|
By YUE LI, Ying Jin
| arxiv.org
Active mobility is widely promoted for sustainable and healthier living, but whether it translates into equitable mental health benefits across individuals and places over time remains unknown. Using causal machine learning and causal deep learning in 264168 UK adults, we find substantial inequalities in individualized effects of active mobility on anxiety, depression, and common mental disorders.
Open in Who Shared Issue with article?

Physiologically Based Pharmacokinetic Modeling to Predict the Pharmacokinetics of Sacubitril/Valsartan in the Elderly with Renal or Hepatic Impairment Population

|
By Ying Jin, Jiaqi Shao BSc, Yingying Yang MSc
| Wiley Online Library Verified
Introduction Sacubitril/valsartan is a fixed-dose combination drug acting as an angiotensin receptor-neprilysin inhibitor.1 It is primarily administered orally and widely used for treating heart failure and hypertension. The compound consists of sacubitril (a prodrug) and valsartan in a 1:1 molar ratio complexed as a sodium salt.
Open in Who Shared Issue with article?
See all 112 licensed articles (120 Total)